EP receptors have potential as biomarkers for cancer prognosis and treatment response. The expression levels of EP2 and EP4, in particular, might indicate the aggressiveness of the tumor and the likelihood of metastasis. These biomarkers could help tailor personalized treatment strategies for patients.
